An interventional study of Radial Extracorporeal Shock Wave Therapy (rESWT) in Stroke, sponsored by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 487 studies in Stroke with a site in Turkey — 96 open to participants now, 109 under way, 3 of them phase 3. Stroke · Turkey.
Among the 487 studies in Stroke with a site in Turkey, this one is the 219th largest by enrollment of the 323 interventional ones that give a count, is one of 71 that started in 2025, is one of 294 with no phase, and was the 435th registered.
8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.
Browse Stroke studies →96 of the 487 studies in Stroke with a site in Turkey are open now. Recruiting first, the newest first:
Izmir City Hospital · Sites in Turkey
Ages 18–90
Izmir City Hospital · Sites in Turkey
Ages 18–90
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–75
Bitlis Eren University · Sites in Turkey
Ages 18–75
Istinye University · Sites in Turkey
Ages 40–70
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
487 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 71 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 48 across 6,049 interventional studies indexed under Stroke.
Median enrollment 40 across the 323 interventional studies, 63 across the 164 observational. Of the 339 that completed or were terminated, 22 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 487 have an industry lead sponsor. The 10 most frequent:
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital is the lead sponsor of 41 studies on the registry; 14 are open to participants now.
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital has 2 studies filed under Stroke — fewer than ten, so there is no comparison to draw.
36 of the studies in Stroke with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07551141Bitlis Eren UniversityEffects of Plantar Vibration on Gait and Balance in Stroke | 2026-11 |
| NCT07550270Gaziler Physical Medicine and Rehabilitation Education and Research HospitalBody Weight-Supported and Virtual Reality Gait Training in Stroke Patients | 2026-11 |
| NCT07948187Nour ABDULRAHIM ALMNLAMirror Therapy With Olfactory-Motor Priming for Arm Recovery After Stroke | 2026-11-22 |
| NCT06166862Karamanoğlu Mehmetbey UniversityAction Observation and Motor Imagery Therapy in Stroke | 2026-12 |
| NCT07822854Nermin KARTVagal Stimulation in Individuals With Stroke | 2026-12-01 |
Add all 36 to your calendar (.ics) → With an account.
Among the 487 studies in Stroke with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Spasticity is a common complication after stroke and can limit upper extremity motor control and activities of daily living. Radial extracorporeal shock wave therapy (rESWT) is a non-invasive treatment that has been investigated for post-stroke spasticity; however, treatment protocols vary widely across studies in the muscles treated, number of impulses, session frequency, energy parameters, and application sites. This prospective, single-center, single-arm study enrolled 30 adults with post-stroke hemiplegia and upper extremity spasticity to evaluate changes in clinical outcomes following an rESWT protocol with anatomically predefined target points. rESWT was applied to the biceps brachii, flexor carpi radialis, and flexor carpi ulnaris of the affected arm twice weekly for 4 weeks (8 sessions). Spasticity, upper extremity motor function, functional independence, quality of life, pain, depressive symptoms, and sensory findings were assessed at baseline, week 4, and week 12.
Rationale: Studies of extracorporeal shock wave therapy for post-stroke spasticity differ in target muscles, number of impulses, session frequency, energy parameters, and application sites, and recent reviews have noted that ESWT protocols are not standardized. This study was designed to describe clinical changes following a single, clearly defined and reproducible rESWT protocol with anatomically predefined target points.
Design and Setting: Prospective, single-center, single-arm, open-label interventional study conducted at the Physical Medicine and Rehabilitation Clinic of Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, İstanbul, Türkiye. All participants received the same intervention; there was no control or sham group.
Intervention: rESWT was delivered using a Modus ESWT device (İnceler Medikal, Ankara, Türkiye) to three muscles of the affected upper extremity: biceps brachii, flexor carpi radialis (FCR), and flexor carpi ulnaris (FCU). Each muscle received 2,000 impulses per session at a frequency of 5 Hz and a pressure of 1.5 bar (6,000 impulses per session in total). Treatment was administered twice weekly for 4 weeks, for a total of 8 sessions (48,000 impulses per participant). Target points were defined using anatomical reference lines based on the EUROMUSCULUS/USPRM spasticity approach: for the biceps brachii, 65% of the reference line between the coracoid process and the medial epicondyle; for the FCR, 35% of the reference line connecting the interepicondylar and interstyloid lines; and for the FCU, the 30% point on the ventral portion of the same reference line. Target sites were identified by palpation and marked on the skin before application, and coupling gel was used to ensure acoustic transmission. All applications were performed by a single operator according to the standardized protocol.
Concomitant Care: All participants had completed a conventional physiotherapy and rehabilitation program before rESWT. No physiotherapy or rehabilitation and no antispastic medication were given during the treatment and follow-up period.
Assessment Schedule: Assessments were performed at baseline (before the first rESWT session), week 4, and week 12. All Modified Ashworth Scale assessments were performed by the same investigator, who was not blinded.
Withdrawal: Participants who received botulinum toxin injections or started a physical therapy and rehabilitation program during the treatment or follow-up period, and participants who did not complete the rESWT sessions or the follow-up assessments, were withdrawn from the study.
Statistical Analysis: Of the 30 enrolled participants, 21 completed the full treatment course and all three assessments and were included in the analyses; missing data were not imputed. Changes across the three time points were analyzed with the Friedman test, and baseline-to-follow-up comparisons with the Wilcoxon signed-rank test, with Holm correction for multiple comparisons. Paired Hodges-Lehmann estimates with bootstrap 95% confidence intervals were calculated. No a priori sample size calculation was performed.
Ethics: The study was approved by the Ethics Committee of Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital (Decision No: 2025/214; Date: 11.06.2025) and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.
The criteria were revised on the registry on Oct 21, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received radial extracorporeal shock wave therapy applied to three muscle groups of the affected upper extremity (biceps brachii, flexor carpi radialis, and flexor carpi ulnaris) at 2,000 impulses per muscle group, 5 Hz frequency, and 1.5 bar pressure, twice weekly for 4 weeks (8 sessions total)
Device: Radial Extracorporeal Shock Wave Therapy (rESWT)
rESWT was delivered to the biceps brachii, flexor carpi radialis, and flexor carpi ulnaris of the affected upper extremity. Parameters: 2,000 impulses per muscle group, 5 Hz, 1.5 bar. Eight sessions administered twice weekly over 4 weeks. Anatomical target points were standardized according to the EUROMUSCULUS/USPRM guideline.
Change From Baseline in Upper Extremity Spasticity Measured by the Modified Ashworth Scale
Spasticity is assessed using the Modified Ashworth Scale (MAS), an ordinal scale measuring resistance to passive movement. Each of seven upper extremity movements (elbow flexion, elbow extension, forearm pronation, forearm supination, wrist flexion, wrist extension, and finger flexion) is graded individually on a 0 to 4 scale, where 0 (minimum) indicates no increase in muscle tone and 4 (maximum) indicates the affected part is rigid. Higher scores indicate greater spasticity (worse outcome).
Time frame: Baseline, at 4 weeks and 12 weeks follow-up
Change From Baseline in Fugl-Meyer Assessment Upper Extremity Motor Function Score
Upper extremity motor function is assessed using the motor function domain of the upper extremity section of the Fugl-Meyer Assessment of Motor Recovery After Stroke (FMA-UE). It consists of 33 items evaluating reflex activity, voluntary movement within and out of synergy, wrist and hand function, and coordination/speed, each scored from 0 (cannot perform) to 2 (performs fully). Total scores range from 0 (minimum) to 66 (maximum). Higher scores indicate better motor function (better outcome).
Time frame: Baseline, at 4 weeks and 12 weeks follow-up
Change from baseline in functional independence
Functional independence is assessed using the Modified Barthel Index (MBI), which evaluates 10 activities of daily living. Total scores range from 0 to 100. Higher scores indicate greater independence (better outcome).
Time frame: Baseline, at 4 weeks and at 12 weeks follow-up
Change From Baseline in Pain Intensity Measured by the Visual Analog Scale
Pain intensity in the affected upper extremity is assessed using the Visual Analog Scale (VAS) for pain, recorded as a single score. Scores range from 0 (minimum; no pain) to 10 (maximum; unbearable pain). Higher scores indicate greater pain intensity (worse outcome).
Time frame: Baseline, at 4 weeks and at 12 weeks follow-up
Change from baseline in stroke-specific quality of life
Quality of life is assessed using the Stroke Specific Quality of Life Scale (SS-QOL), a 49-item instrument covering 12 domains, each item scored on a 1 to 5 Likert scale. Total scores range from 49 to 245. Higher scores indicate better quality of life (better outcome).
Time frame: Baseline, at 4 weeks and at 12 weeks follow-up
Change from baseline in depressive symptom severity
Depressive symptom severity is assessed using the Beck Depression Inventory (BDI), a 21-item self-report scale with each item scored from 0 to 3. Total scores range from 0 to 63. Higher scores indicate greater depressive symptom severity (worse outcome).
Time frame: Baseline, at 4 weeks, and at 12 weeks follow-up
Change from baseline in proprioception
Joint position sense of the affected upper extremity is assessed via standard clinical examination and categorized as intact, impaired, or not assessable.
Time frame: Baseline, at 4 weeks and at 12 weeks follow-up
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2025 to primary completion in May 2026, 10 months.
Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 10 months is below that.
Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Apr 2026 → May 2026 and completion Apr 2026 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital